• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

EGFR-mutated lung cancer

Stop sign and red lights at traffic intersection
Pharma

Tagrisso rival loses EU approval after AZ legal challenge

EU regulators revoked Aumseqa’s approval after the EMA ruled that Hansoh’s application illegally referenced AstraZeneca’s Tagrisso.
Angus Liu Sep 30, 2026 11:13am
lung

Biokin, BMS' bispecific ADC hits goal in China lung cancer trial

Aug 18, 2026 11:18am
AZ

AstraZeneca dual lung cancer wins softened by bispecific fail

Aug 17, 2026 10:56am
Better beat improve roll

Summit updates ivonescimab survival data ahead of PDUFA

Jul 22, 2026 10:58am
AstraZeneca

AstraZeneca buys lung cancer drug Zegfrovy from Dizal for $1.5B

Jul 14, 2026 9:57am
Two fencers spar in a stadium

Dizal takes on J&J with first-line win in EGFR lung cancer type

May 29, 2026 8:00am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings